Secondary analysis of the TESTING trial (483 patients with IgA nephropathy): predicted individual absolute risk reduction with methylprednisolone ranged from −10% to 40% (average 16.1%); those predicted >10% had observed ARR 24% vs −5% for the rest.
Secondary analysisn = 483
Canney et al. A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy